RecruitingInterventional · Phase 3NCT04064060 ↗A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsSujit ShethPIInterventionDrug: LuspaterceptDates
Active, not recruitingInterventional · Phase 1NCT04279847 ↗A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsEllen K. RitchiePIInterventionDrug: INCB057643 · Drug: RuxolitinibDatesFeb 2021 – Apr 2027 (est.)SponsorIncyte CorporationMyelofibrosisMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome+4 more
Active, not recruitingInterventional · Phase 3NCT04285086 ↗A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.Ghaith Abu-ZeinahPIInterventionBiological: Ropeginterferon alfa-2b · Drug: AnagrelideDatesAug 2020 – Nov 2024SponsorPharmaEssentiaEssential Thrombocythemia
Active, not recruitingInterventional · Phase 2NCT04802161 ↗Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML With MDS-Related ChangesGail J RobozPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Drug: Liposome-encapsulated Daunorubicin-Cytarabine · Drug: PomalidomideDatesAug 2022 – Nov 2024· Results postedSponsorNational Cancer InstituteAcute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia With Multilineage Dysplasia+3 more
Active, not recruitingInterventional · Phase 2NCT05482971 ↗A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential ThrombocythemiaGhaith Abu-ZeinahPIInterventionDrug: Ropeginterferon alfa-2b-njft (P1101)DatesSep 2022 – May 2025SponsorPharmaEssentiaEssential Thrombocythemia
Active, not recruitingInterventional · Phase 2NCT05600894 ↗Venetoclax In Combination With ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 TrialGail J RobozPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Decitabine and Cedazuridine · Drug: VenetoclaxDatesJun 2023 – Aug 2027 (est.)SponsorNational Cancer InstituteChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blasts+2 more
Active, not recruitingInterventional · Phase 1NCT06313593 ↗A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative NeoplasmsJoseph M ScanduraPIInterventionDrug: INCB160058 · Drug: Standard disease-directed therapyDatesAug 2024 – Oct 2028 (est.)SponsorIncyte CorporationMyeloproliferative Neoplasms
Active, not recruitingInterventional · Phase 3NCT06468033 ↗A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension StudyGhaith Abu-ZeinahPIInterventionBiological: Ropeginterferon alfa-2b · Other: PlaceboDatesJul 2025 – Nov 2027 (est.)SponsorPharmaEssentiaPrimary MyelofibrosisMyeloproliferative Neoplasm
RecruitingInterventional · Phase 2NCT06661915 ↗A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)Ghaith Abu-ZeinahPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Decitabine and Cedazuridine · Drug: IadademstatDatesAug 2025 – Dec 2027 (est.)SponsorNational Cancer InstituteAccelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential Thrombocythemia+5 more
CompletedInterventional · Phase 1/2NCT02158858 ↗A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)Joseph M ScanduraPIInterventionDrug: Pelabresib · Drug: RuxolitinibDatesJul 2014 – Jan 2025· Results postedSponsorConstellation PharmaceuticalsMyelofibrosisLeukemia, Myelocytic, AcuteMyelodysplastic/Myeloproliferative Neoplasm+11 more
CompletedInterventional · Phase 2NCT03011372 ↗A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)Ellen K. RitchiePIInterventionDrug: PemigatinibDatesApr 2017 – Oct 2024· Results postedSponsorIncyte, Inc.MPN (Myeloproliferative Neoplasms)
TerminatedInterventional · Phase 2NCT04103645 ↗A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)Joseph M ScanduraPIInterventionDrug: VactosertibDatesNov 2019 – Jul 2024· Results postedSponsorWeill Medical College of Cornell UniversityMyeloproliferative Neoplasm
TerminatedInterventional · Phase 1NCT04637009 ↗A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsGail J RobozPIInterventionDrug: TAS1553DatesDec 2020 – Feb 2023SponsorAstex Pharmaceuticals, Inc.Acute Myeloid LeukemiaMyeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm